Which treatment regimen does bevacizumab belong to?

Bevacizumab (Bevacizumab) belongs to the "targeted anti-angiogenesis therapy" program in tumor treatment. It is a biological agent widely used in a variety of advanced solid tumors internationally. The drug mainly inhibits the formation of new blood vessels in tumor tissue by blocking the binding of vascular endothelial growth factor A (VEGF-A) to its receptors. The growth of tumors is inseparable from blood vessel supply, and bevacizumab is designed based on this therapeutic logic of "cutting off blood supply" and is one of the representative drugs against tumor angiogenesis.

It is not used on its own to treat most tumors, but rather as a combination drug in standard chemotherapy regimens. For example, in the treatment of non-small cell lung cancer, bevacizumab is often combined with pemetrexed and cisplatin to form a first-line regimen; in metastatic colorectal cancer, it is used in combination with FOLFIRI or FOLFOX regimen; in gynecological tumors such as cervical cancer or ovarian cancer, it can also be used as a maintenance treatment drug to delay the progression of the disease. In addition, bevacizumab is also being included in immune combination therapy strategies, such as new treatment models combined with PD-1/PD-L1 inhibitors for tumors such as hepatocellular carcinoma and clear cell renal cell carcinoma.

With the advancement of precision medicine, the application of this drug is continuously expanding, gradually transitioning from traditional chemotherapy combination to multi-dimensional targeted combination. The goal of treatment is not only to prolong survival, but also to control symptoms, improve quality of life and delay the occurrence of drug resistance. Overall, bevacizumab belongs to the category of targeted drugs in tumor treatment, often occupies a key position in multi-line treatment programs, and has become an indispensable component of modern anti-cancer strategies. When doctors choose a treatment plan, they usually decide whether to include bevacizumab as part of the combination therapy based on multiple factors such as the patient's specific condition, biomarker expression, and tolerability assessment.

Reference materials:https://www.drugs.com/bevacizumab.html